Commentary|Articles|April 23, 2026

FAQ: Insights on On-Body Injector for Anti-CD38 in Multiple Myeloma

Author(s)Jonah Feldman, Sikander Ailawadhi, MD

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending the approval of subcutaneous (SC) administration of isatuximab (Sarclisa).¹ Although it is not the first subcutaneous therapy in multiple myeloma, the use of an on-body injector (OBI) in the supporting phase 3 IRAKLIA trial (NCT05405166) gives the topic of subcutaneous administration even greater promise to improve patient convenience.